This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Be Thankful to These Outperforming Sector ETFs This Year
by Sanghamitra Saha
Despite occasional trade tensions, U.S. equity gauges have added solid gains this year. But these sector ETFs handily beat the soaring broader market.
5 Amazing ETF Strategies for Q2
by Sweta Killa
Here are some strategies that could prove extremely beneficial for ETF investors in the second quarter.
Top ETF Stories of February
by Sanghamitra Saha
Inside the top ETF events of the month of February.
Trump-Jingping Truce to Boost These ETFs
by Sanghamitra Saha
Xi Jinping and Trump agree on not announcing any new tariff for 90 days, putting these ETFs in focus.
Further Selloffs Ahead? ETF Strategies to Follow
by Sanghamitra Saha
These ETF strategies may help investors if there are more selloffs in Wall Street.
Implied Volatility Surging for Quintiles IMS Holdings (Q) Stock Options
by Zacks Equity Research
Quintiles IMS Holdings (Q) needs Investors to pay close attention to the stock based on moves in the options market lately.
MedTech Stocks to Top Q2 Estimates
by Zacks Equity Research
Most of the MedTech majors are lined up to report their earnings results over the next week.
Should You Buy Quintiles IMS Holdings (Q) Ahead of Earnings?
by Zacks Equity Research
Quintiles IMS Holdings (Q) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Quintiles' (Q) OCE Software to Simplify Commercial Functions
by Zacks Equity Research
QuintilesIMS (Q) announced the general availability of Orchestrated Customer Engagement (OCE) software to streamline pharmaceutical commercial functions.
Quintiles IMS Holdings (Q) Holds Secondary Offering (revised)
by Zacks Equity Research
Q held a secondary offering of 10.6m shares, of which they repurchased $300m worth.
Quintiles IMS Holdings (Q) to Repurchase 10.6M Common Share
by Zacks Equity Research
Quintiles IMS Holdings, Inc. (Q) announced that it will repurchase 10,571,003 shares of its common stock.
Healthcare Stock Q4 Earnings Slated for Feb 14: ESRX, CRL, Q
by Zacks Equity Research
Let's take a sneak peek at a few major Healthcare stocks slated to release their fourth-quarter numbers on Feb 14:
Teladoc to Provide Diagnostic Service Via Analyte Health
by Zacks Equity Research
Teladoc (TDOC) has tied up with Analyte Health to provide lab diagnostics services through its telehealth platform.
Teladoc (TDOC) December Business Reveals Outperformance
by Zacks Equity Research
Teladoc Inc. (TDOC) disclosed that in the month of December it crossed more than two million patient visits.
Is Cooper Companies (COO) Poised for Earnings Beat in Q4?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report fourth-quarter fiscal 2016 results after the market closes on Dec 8.